CHICAGO — Alexandre Lebeaut, MD, head of research and development at Ipsen Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and promising investigational agents in its pipeline.
ASCO presentations spotlighted data from trials that evaluated cabozantinib (Cabometyx) for patients with advanced hepatocellular carcinoma or metastatic gastrointestinal stromal tumor. Other abstracts focused on use of liposomal irinotecan injection for patients with small cell lung cancer, and the use of lanreotide autogel for treatment of clinical

Source link